TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06796504: The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Sponsor: SetPoint Medical Corporation · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,474,400

Rescue Site Savings

+$970,000

Unlock Full NCT06796504 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06796504 Rescue Dossier →